Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 17/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.84 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dotinurad SCHEMBL10322525 | 0.91 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| Dotinurad SCHEMBL29935445 | 0.91 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| Dotinurad SCHEMBL27088403 | 0.90 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| Dotinurad SCHEMBL28372873 | 0.90 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| Dotinurad SCHEMBL29994905 | 0.90 | SLC22A12 (0.97) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| SCHEMBL10322774 | 0.86 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2 | |
| SCHEMBL10322939 | 0.85 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2 | |
| SCHEMBL10323009 | 0.84 | SLC22A12 (0.69) | SLC22A12CYP2C9ABCG2HSD11B1 | |
| SCHEMBL10323387 | 0.83 | SLC22A12 (0.78) | SLC22A12CYP2C9ABCG2 | |
| SCHEMBL10322041 | 0.83 | SLC22A12 (1.00) | SLC22A12CYP2C9ABCG2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484669-B1 | PHENOL DERIVATIVES | FUJI YAKUHIN CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| CN-102639518-B | Novel Phenol Derivatives | FUJI YAKUHIN CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8367843-B2 | Phenol derivative | FUJI YAKUHIN CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| CN-102639518-A | Novel Phenol Derivatives | FUJI YAKUHIN CO LTD | 2012-08-15 | — | — | CN | disclosed |
| EP-2484669-A1 | NOVEL PHENOL DERIVATIVE | Fuji Yakuhin Co., Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | FUJI YAKUHIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | XDH, REN, UTS2R | SLC22A12 379/4885CYP2C9 184/4885ABCG2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.